TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity

✍ Scribed by Teresa R. Johnson; Srinivas Rao; Robert A. Seder; Man Chen; Barney S. Graham

• Book ID: 116961489
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 730 KB
• Volume: 27
• Category: Article
• ISSN: 0264-410X
• DOI: 10.1016/j.vaccine.2009.03.026